Notch signaling and targeted therapy in non-small cell lung cancer
Copyright © 2024 Elsevier B.V. All rights reserved..
The Notch signaling pathway plays pivotal roles in cell proliferation, stemness and invasion of non-small cell lung cancer (NSCLC). The human Notch family consists of four receptors, namely Notch1, Notch2, Notch3, and Notch4. These receptors are transmembrane proteins that play crucial roles in various cellular processes. Notch1 mostly acts as a pro-carcinogenic factor in NSCLC but sometimes acts as a suppressor. Notch2 has been demonstrated to inhibit the growth and progression of NSCLC, whereas Notch3 facilitates these biological behaviors of NSCLC. The role of Notch4 in NSCLC has not been fully elucidated, but it is evident that Notch4 promotes tumor progression. At present, drugs targeting the Notch pathway are being explored for NSCLC therapy, a majority of which are already in the stage of preclinical research and clinical trials, with bright prospects in the clinical treatment of NSCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:585 |
|---|---|
| Enthalten in: |
Cancer letters - 585(2024) vom: 31. März, Seite 216647 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun, Jiajun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Crosstalk |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 05.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canlet.2024.216647 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367912724 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367912724 | ||
| 003 | DE-627 | ||
| 005 | 20240305232303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2024.216647 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM367912724 | ||
| 035 | |a (NLM)38301911 | ||
| 035 | |a (PII)S0304-3835(24)00041-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Jiajun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Notch signaling and targeted therapy in non-small cell lung cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a The Notch signaling pathway plays pivotal roles in cell proliferation, stemness and invasion of non-small cell lung cancer (NSCLC). The human Notch family consists of four receptors, namely Notch1, Notch2, Notch3, and Notch4. These receptors are transmembrane proteins that play crucial roles in various cellular processes. Notch1 mostly acts as a pro-carcinogenic factor in NSCLC but sometimes acts as a suppressor. Notch2 has been demonstrated to inhibit the growth and progression of NSCLC, whereas Notch3 facilitates these biological behaviors of NSCLC. The role of Notch4 in NSCLC has not been fully elucidated, but it is evident that Notch4 promotes tumor progression. At present, drugs targeting the Notch pathway are being explored for NSCLC therapy, a majority of which are already in the stage of preclinical research and clinical trials, with bright prospects in the clinical treatment of NSCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Crosstalk | |
| 650 | 4 | |a Drug resistance | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a Notch | |
| 650 | 4 | |a Targeted therapy | |
| 650 | 7 | |a Receptor, Notch1 |2 NLM | |
| 650 | 7 | |a Receptors, Notch |2 NLM | |
| 650 | 7 | |a Receptor, Notch2 |2 NLM | |
| 650 | 7 | |a Receptor, Notch3 |2 NLM | |
| 700 | 1 | |a Dong, Meichen |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shubing |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Doudou |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 585(2024) vom: 31. März, Seite 216647 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
| 773 | 1 | 8 | |g volume:585 |g year:2024 |g day:31 |g month:03 |g pages:216647 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2024.216647 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 585 |j 2024 |b 31 |c 03 |h 216647 | ||